Share on StockTwits

Prothena Co. PLC (NASDAQ:PRTA)’s share price gapped up prior to trading on Friday after an insider bought additional shares in the company, StockRatingsNetwork reports. The stock had previously closed at $19.45, but opened at $19.52. Prothena Co. PLC shares last traded at $20.29, with a volume of 156,203 shares changing hands.

Specifically, Insider Arthur W. Homan acquired 2,000 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were purchased at an average cost of $19.12 per share, with a total value of $38,240.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on PRTA. Analysts at Zacks upgraded shares of Prothena Co. PLC from a “neutral” rating to an “outperform” rating in a research note on Tuesday. They now have a $20.00 price target on the stock. Separately, analysts at Oppenheimer initiated coverage on shares of Prothena Co. PLC in a research note on Thursday, July 10th. They set an “outperform” rating and a $40.00 price target on the stock. Finally, analysts at Ladenburg Thalmann initiated coverage on shares of Prothena Co. PLC in a research note on Thursday, May 22nd. They set a “buy” rating and a $36.50 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $37.44.

The stock’s 50-day moving average is $20.34 and its 200-day moving average is $26.97. The company’s market cap is $561.5 million.

Prothena Co. PLC (NASDAQ:PRTA) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.06 earnings per share (EPS) for the quarter. The company had revenue of $15.10 million for the quarter.

Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.